Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/IIa Study of EGFR-Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (E-EDV-D682) with Concurrent Immunomodulatory Adjuvant Non-Targeted EDVs carrying an immunomodulator (EDV-GC) in (i) Cohort 1, Subjects with Advanced Pancreatic Cancer and (ii) Cohort 2, Subjects with other EGFR Expressing Solid Tumours, who have Failed First or Second-line Therapy or where other Standard Therapies are not Appropriate
EnGeneIC Pty Ltd
All patients enrolled in this clinical trial will receive a combination treatment, which contains the EnGeneIC Dream Vector (EDV(TM)), the study drug (chemotherapy) and the bispecific antibody. Treatment will be given in 8-week cycles and is combined in a syringe and administered intravenously, over a period of 20 minutes using a special pump. One dose of the treatment is given each week for the first 7 weeks, followed by a treatment free week (week 8) where a CT or MRI scan is performed to evaluate the tumours response.